These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36621846)

  • 41. The Metabolic Signature of AML Cells Treated With Homoharringtonine.
    Zhang Y; Li N; Chang Z; Wang H; Pei H; Zhang D; Zhang Q; Huang J; Guo Y; Zhao Y; Pan Y; Chen C; Chen Y
    Front Oncol; 2022; 12():931527. PubMed ID: 35774129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR.
    Tang YJ; Wu W; Chen QQ; Liu SH; Zheng ZY; Cui ZL; Xu JP; Xue Y; Lin DH
    BMC Cancer; 2022 Aug; 22(1):909. PubMed ID: 35986311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homoharringtonine inhibits fibroblasts proliferation, extracellular matrix production and reduces surgery-induced knee arthrofibrosis via PI3K/AKT/mTOR pathway-mediated apoptosis.
    Sun Y; Dai J; Jiao R; Jiang Q; Wang J
    J Orthop Surg Res; 2021 Jan; 16(1):9. PubMed ID: 33407698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
    Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
    PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia.
    Zhou X; Liang S; Zhan Q; Yang L; Chi J; Wang L
    Cell Death Dis; 2020 Jun; 11(6):492. PubMed ID: 32606327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CTSB Knockdown Inhibits Proliferation and Tumorigenesis in HL-60 Cells.
    Peng S; Yang Q; Li H; Pan Y; Wang J; Hu P; Zhang N
    Int J Med Sci; 2021; 18(6):1484-1491. PubMed ID: 33628106
    [No Abstract]   [Full Text] [Related]  

  • 47. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.
    Bao F; Zhang L; Pei X; Lian C; Liu Y; Tan H; Lei P
    PLoS One; 2021; 16(9):e0256995. PubMed ID: 34587164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
    Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
    Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overexpression of long noncoding RNA HOXA-AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia.
    Qu Y; Wang Y; Wang P; Lin N; Yan X; Li Y
    Cell Biol Int; 2020 Aug; 44(8):1745-1759. PubMed ID: 32369230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.
    Liu HY; Dong TX; Li ZZ; Li TT; Jiang J; Zhu MW; An TT; Chen YD; Yang XH
    Neoplasma; 2021 Sep; 68(5):924-937. PubMed ID: 33998239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia.
    Fu Y; Xu M; Cui Z; Yang Z; Zhang Z; Yin X; Huang X; Zhou M; Wang X; Chen C
    EBioMedicine; 2020 Feb; 52():102664. PubMed ID: 32062360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive bioinformatic analysis of the expression and prognostic significance of TSC22D domain family genes in adult acute myeloid leukemia.
    Xu X; Sun R; Li Y; Wang J; Zhang M; Xiong X; Xie D; Jin X; Zhao M
    BMC Med Genomics; 2023 May; 16(1):117. PubMed ID: 37237254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling.
    Liu L; Yang L; Liu X; Liu M; Liu J; Feng X; Nie Z; Luo J
    J Transl Med; 2022 Jul; 20(1):304. PubMed ID: 35794581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway.
    Ma L; Kuai WX; Sun XZ; Lu XC; Yuan YF
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7867-7876. PubMed ID: 30536332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway.
    Nie D; Ma P; Chen Y; Zhao H; Liu L; Xin D; Cao W; Wang F; Meng X; Liu L; Xie M; Sun L
    Hematology; 2021 Dec; 26(1):931-939. PubMed ID: 34789086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
    Liang X; Xia R
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34792179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.
    Jiang D; Wu X; Sun X; Tan W; Dai X; Xie Y; Du A; Zhao Q
    J Nanobiotechnology; 2022 Jan; 20(1):29. PubMed ID: 35012554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Downregulation of GNA15 Inhibits Cell Proliferation
    Li M; Liu Y; Liu Y; Yang L; Xu Y; Wang W; Jiang Z; Liu Y; Wang S; Wang C
    Front Oncol; 2021; 11():724435. PubMed ID: 34552875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
    Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.